Syon Capital LLC Purchases New Shares in Moderna, Inc. (NASDAQ:MRNA)

Syon Capital LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,134 shares of the company's stock, valued at approximately $463,000.

A number of other large investors also recently bought and sold shares of the stock. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the period. Compass Planning Associates Inc purchased a new stake in Moderna in the 4th quarter worth $37,000. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. purchased a new position in Moderna in the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. The Goldman Sachs Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Morgan Stanley dropped their price target on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. Finally, Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Moderna currently has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Stock Up 0.8 %

Shares of MRNA traded up $0.21 during trading hours on Wednesday, reaching $28.03. The stock had a trading volume of 1,990,425 shares, compared to its average volume of 7,347,784. The firm has a 50-day moving average of $29.91 and a 200 day moving average of $38.08. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47. The company has a market cap of $10.84 billion, a P/E ratio of -3.02 and a beta of 2.23.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.